Double-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's disease
Phase 3
- Conditions
- Parkinson's disease
- Registration Number
- JPRN-jRCT2080220368
- Lead Sponsor
- Dainippon Sumitomo Pharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
[Major inclusion criteria]
- Patients with reduced response to L-DOPA
- Age: >=20 and <75 (at the time of informed consent)
[Major exclusion criteria]
- Patients with Parkinson's syndrome other than Parkinson's disease
- Patients with epilepsy
- Patients with a history of treatment with zonisamide, or who have ever enrolled in other clinical trials related to AD-810N
- Patients with a history of neuroleptic malignant syndrome
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method